The MDS Non-Motor Rating Scale (MDS-NMS): A new measure for non-motor Parkinson’s disease

Introduction

The MDS Non-Motor Rating Scale (MDS-NMS): A new measure for non-motor Parkinson’s disease

Course Format

Webinar

Release Date

August 14, 2020

Expiration Date

September 30, 2022

Program Description

The MDS Non-Motor Rating Scale (MDS-NMS): A new measure for non-motor Parkinson’s disease webinar will provide an overview of the new scale, demonstrate how it compares to the original NMSS, and present information that clinicians and clinical trial raters should have to administer and use the instrument.

The MDS-NMS is a state of the art and up to date revision of the Non-Motor Symptoms Scale (NMSS), a widely used scale in the field of Movement Disorders clinical practice and trials since 2007. The MDS-NMS was developed to improve and refine the assessment of non-motor symptoms in Parkinson’s disease (PD) and more fully cover aspects of non-motor Parkinson’s symptoms which have evolved over the last 10 years. This rater-completed assessment measures frequency and severity of 13 non-motor domains (as opposed to nine domains in the original NMSS), over 52 items and covers a range of key non-motor symptoms both PD and treatment related, and in greater depth, compared with the NMSS. The scale also has a new MDS-NMS Non-Motor Fluctuations (NMF) Subscale to assess changes in non-motor symptoms in relation to the timing of anti-parkinsonian medications across 8 domains.

Course has been expired

Faculty

K. Ray Chaudhuri, DSc, FRCP, MD - King’s College London, London, United Kingdom

Pablo Martinez-Martin, MD, PhD - National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain

Anette Schrag, FRCP, PhD - UCL Queen Square Institute of Neurology, London, United Kingdom

Daniel Weintraub, MD - Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Course Purpose

The primary purpose of this program is to provide information on ratings scales.

Learning Objectives

Upon completion of this activity learners will be able to:

1. Discuss key characteristics of the MDS-NMS including, but not limited to, the domains measured by the MDS-NMS, time to administer and information about the reliability and reproducibility of the scale

2. Understand the differences between the MDS-NMS and the original NMSS

3. Understand the populations and disease conditions for which the scale can be used

4. Understand how to administer and score the MDS-NMS

Intended Audience

This activity is intended for clinicians that are treating Parkinson’s disease patients, clinical trial representatives and raters from all health care professional backgrounds.

Method of Participation

The course must be attended in their entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

Faculty Disclosure

NMS20WEB-Disc

Accreditation and Credit Designation

The International Parkinson and Movement Disorder Society designates this education activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Hardware and Software Requirement

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.

2. Compatible with Windows PC and MAC (256 MB of RAM or higher)

3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher

4. Adobe Flash Player 12.0 (or higher).

5. Adobe Reader to print certificate.

Staff Disclosure

MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

All individuals in control of content for this course are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME.